TP53 and cancer: Although our study is limited with overexpression of these mutant p53s in cancer cells mainly due to the fact that there is no such cancer cell line that harbors available p53LC, our findings that p53LCs can act as the DN suppressor of wt p53 (Figure 5E) are valuable to clinical therapeutic designs for those cancers that harbor these p53 mutations and also offer new targets for future development of personalized anticancer drugs against these cancers.